The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response

Thrombosis and Haemostasis

Volumn 103, Issue 5, 2010, Pages 920-925

  Harmsze, Ankie M ^a,b   Robijns, Karen ^a   Van Werkum, Jochem W ^a   Breet, Nicoline J ^a   Hackeng, Christian M ^a   Ten Berg, Jurrien M ^a   Ruven, Hendrik J T ^a   Klungel, Olaf H ^b   De Boer, Anthonius ^b   Deneer, Vera H M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Calcium channel blockers; Clopidogrel; CYP3A4; Drug drug interaction; P glycoprotein; Percutaneous coronary intervention; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMLODIPINE; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DILTIAZEM; GLYCOPROTEIN P; MEPIRODIPINE; NIFEDIPINE; VERAPAMIL; MULTIDRUG RESISTANCE PROTEIN; TICLOPIDINE;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; ANGIOPLASTY; ANTAGONISTS AND INHIBITORS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; THROMBOCYTE ACTIVATION;

AGED; AMLODIPINE; ANGIOPLASTY; BLOOD PLATELETS; CALCIUM CHANNEL BLOCKERS; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 77952048536     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-08-0516     Document Type: Article

References (29)

1. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533. (Pubitemid 32772726)
2. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
3. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
4. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-1295. (Pubitemid 35265838)
5. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
6. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251. (Pubitemid 40094733)
7. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247. (Pubitemid 44497506)
8. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
9. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
10. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30: 916-922.
11. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
12. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-offunction polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806-811.
13. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895-1900.
14. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. Cmaj 2006; 174: 1715-1722.
15. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-2436.
16. Harmsze A, van Werkum JW, Bouman HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 2010; 20: 18-25.
17. Katoh M, Nakajima M, Yamazaki H, et al. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 2000; 17: 1189-1197.
18. Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
19. Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010; 96: 186-189.
20. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
21. von Beckerath N, Pogatsa-Murray G, Wieczorek A, et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 2006; 95: 910-911.
22. van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006; 4: 2516-2518.
23. van Werkum JW, Harmsze AM, Elsenberg EH, et al. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008; 19: 479-488.
24. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425. (Pubitemid 44522148)
25. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000. (Pubitemid 351844676)
26. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-134.
27. Mahgoub AA, El-Medany AH, Abdulatif AS. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure. Saudi Med J 2002; 23: 725-731.
28. Kirch W, Hutt HJ, Dylewicz P, et al. Dose-dependence of the nifedipine-digoxin interaction? Clin Pharmacol Ther 1986; 39: 35-39.
29. Rodin SM, Johnson BF, Wilson J, et al. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988; 43: 668-672.